Skip to content

Pharmacodynamic study of remimazolam for anxiety patients undergoing painless gastroscopy

Pharmacodynamic study of remimazolam for anxiety patients undergoing painless gastroscopy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086957
Enrollment
Unknown
Registered
2024-07-15
Start date
2024-02-05
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anxiety

Interventions

Group A (Anxiety Self Rating Scale score less than 50 points,depth of sedation observed):Upward and Downward Adjustment of remimazolam-Inducing Drug Doses by the Biased Coin Sequencing Method
Group B ((Anxiety Self Rating Scale score greater than or equal to 50, observe the depth of sedation):Upward and Downward Adjustment of remimazolam-Inducing Drug Doses by the Biased Coin Sequencing Me
Group C(Anxiety Self Rating Scale score less than 50 points,Observe the somatokinetic reaction):Upward and Downward Adjustment of remimazolam-Inducing Drug Doses by the Biased Coin Sequencing Method
Grou D(Anxiety Self Rating Scale score greater than or equal to 50,Observe the somatokinetic reaction):Upward and Downward Adjustment of remimazolam-Inducing Drug Doses by the Biased Coin Sequencing M

Sponsors

Shaoxing People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) ASA Grade I to II agrees to participate in this experiment and signs a written informed consent; (2) Age 18-60 years; (3)Body mass index (BMI) : 18.5 ~ 28kg/m^2; (4) Patients undergoing elective painless gastroscopy.

Exclusion criteria

Exclusion criteria: 1) Patients with mental illness, long-term use of psychotropic drugs and alcohol or drug abuse; (2) Patients with neurological diseases such as dementia and Parkinson's disease, and previous history of cerebrovascular accidents or craniocerebral surgery; (3) Patients with severe visual or hearing impairment and difficulties in language communication; (4) Patients with obvious liver and kidney dysfunction and serious cardiopulmonary disease; (5) Allergic or contraindicated to benzodiazepines, opioids and drug components.

Design outcomes

Primary

MeasureTime frame
the median effective effect-concentration;the 90% effective effect-concentration;95% confidence interval;

Countries

China

Contacts

Public ContactHu Shuangyan

Shaoxing People's Hospital

hushuangyan120@163.com+86 137 7731 2269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026